COL7A1 and generalized dominant dystrophic epidermolysis bullosa: Using the Amaxa Nucleofector 2 device (Lonza), Shinkuma et al. delivered CRISPR/Cas9 plasmid into the iPSCs to target a dominant negative mutation (c.8068_8084delinsGA) of COL7A1 gene in dominant dystrophic epidermolysis bullosa (DDEB).